Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Patent
1995-09-22
1998-12-01
Fitzgerald, David L.
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
435 691, 4351723, 4352523, 43525411, 4353201, 435348, 530350, 536 231, 536 235, 536 241, 536 2431, 536 2433, 514 2, 514 8, 514 12, C07K 14435, C07K 14475, C12N 510, C12N 1512
Patent
active
058437754
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The invention generally relates to growth factors and neurotrophic factors, and more particularly to a soluble growth factor with dorsal growth inducing activity, to complexes including the factor, and to DNA or RNA coding sequences for the factor.
This invention was made, in part, with government support under Grant Contract No. ROI-GM-42341, awarded by the National Institutes of Health. The government has certain rights in this invention.
BACKGROUND OF THE INVENTION
Growth factors are substances, such as polypeptide hormones, which affect the growth of defined populations of animal cells in vivo or in vitro, but which are not nutrient substances. Proteins involved in the growth and differentiation of tissues may promote or inhibit growth, and promote or inhibit differentiation, and thus the general term "growth factor" includes cytokines and trophic factors. Among growth, or neurotrophic factors presently known are those that can be classified into the insulin mammary stimulating factor (MSF), and nerve growth factor (NGF)!; those factor (EGF) and transforming growth factors (TGF.alpha., TGF.beta., TGF.gamma.)!; those classified into the platelet-derived growth factor factor (ODGF), and fibroblast growth factor (FGF)!; the neurotrophins factor (CSF), T-cell growth factor, tumor angiogenesis factor (TAF), DNA synthesis promoting factor (DSF), tumor-derived growth factors, fibroblast-derived growth factor (FDGF)!.
Receptors that affect growth (that is, receptors for growth-associated ligands) are proteins found associated with cell surfaces that specifically bind their growth factors as ligands. Growth factor receptors are utilized in various clinical and diagnostic applications.
U.S. Pat. No. 4,857,637, issued Aug. 15, 1989, inventors Hammonds et al., describes a method for immunizing an animal against its growth hormone receptor through use of vaccinating with antibodies in order to stimulate growth of the animals.
U.S. Pat. No. 4,933,294, issued Jun. 12, 1990, inventors Waterfield et al., describes studies of structural alterations of the human EGF receptor and its gene and a relationship in tumorigenesis for assays and therapies involving the human EGF receptor. For example, such assays can involve detection of structurally altered or abnormally expressed growth factor receptor and the mRNA transcripts and genes which encode them. EGF may have a role in cell proliferation and differentiation since it induces early eyelid opening and incisor development in new born mice.
U.S. Pat. No. 5,030,576, issued Jul. 9, 1991, inventors Dull et al., describes the role of receptors, such as receptors for growth factors, in designing drugs by the pharmaceutical industry, and discloses use of a receptor hybrid for screening drug purposes, such as in studies of EGF binding domains. U.S. Pat. No. 5,087,616, issued Feb. 11, 1992, inventors Myers and Bichon, describes a method for destroying tumor cells with a composition including a drug conjugate. The conjugate has a growth factor as one moiety and a polymeric carrier with a cytotoxic compound as another moiety. Thus, compositions of the patent are described as binding preferentially to tumor cells bearing EGF-binding receptors (when an EGF growth factor, for example, is used as a first moiety).
U.S. Pat. No. 5,098,833, issued Mar. 24, 1992, inventors Lasky, et al., describes a DNA isolant capable of hybridizing to the epidermal growth factor domain. Expression systems for recombinant production are said to be useful in therapeutic or diagnostic compositions.
A good background review of a neurotrophic factor related to NGF is provided by W092/05254, published Apr. 2, 1992, which also describes state of the art methods of: preparing amino acid sequence variations, site-directed mutagenesis techniques, ligation of coding DNA into a replicable vector for further cloning or for expression, choice of promoters for expression vectors, suitable host cells for expression, particularly mammalian cells, protein purification upon recovery from culture m
REFERENCES:
patent: 4857637 (1989-08-01), Hammonds et al.
patent: 4933294 (1990-06-01), Waterfield et al.
patent: 5030576 (1991-07-01), Dull et al.
patent: 5177197 (1993-01-01), Kanzaki et al.
patent: 5219759 (1993-06-01), Heldin et al.
patent: 5229500 (1993-07-01), Barde et al.
patent: 5364769 (1994-11-01), Rosenthal
Basler, et al., "Control of Cell Pattern in the Neural Tube: Regulation of Cell Differentiation by dorsalin-1, a Novel TGF.beta. Family Member," Cell, 73, (May 21, 1993), pp. 687-702.
Chen, et al., "The Proto-Oncogene C-ros Codes for a Transmembrane Tyrosine Protein Kinase Sharing Sequence and Structural Homology . . . ," Oncogene, 6 (1991), pp. 257-264.
Christian, et al., "Xwnt-8, a Xenopus Wnt-1/int-1-related Gene Responsive to Mesoderm-inducing Growth Factors, May Play A Role in Ventral Mesodermal Patterning During Embryogenesis," Development, 111 (1991), pp. 1045-1055.
Lin, et al., "GDNF: A Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons," Science, 260 (May 21, 1993), pp. 1130-1132.
Sokol, et al., "A Mouse Macrophage Factor Induces Head Structures and Organizes a Body Axis in Xenopus," Science, 249 (1990), pp. 561-564.
Weiss, Rick, "Promising Protein for Parkinson's," Science, 260 (May 21, 1993), pp. 1072-1703.
Lamb, "Neural Induction by The Secreted Polypeptide Noggin", Science 262: (1993), pp. 713-718.
Smith, "Secreted Noggin Protein Mimics the Spemann Organizer in Dorsalizing Xenopus Mesoderm", Nature 361, (1993) pp. 547-549.
Slack, "Developmental Biology. Noggin the Dorsalizer", Nature 361, (1993), pp. 498-499.
Smith, "Expression Cloning of Noggin, a New Dorsalizing Factor Localized to the Spemann Organizer in Xenopus Embryos", Cell 70, (1992), pp. 829-840.
Smith, et al, "Injected Xwnt-8 RNA Acts Early in Xenopus Embryos to Promote Formation of a Vegetal Dorsalizing Center", Cell 67, (1991), pp. 753-765.
Chalazonitis, et al., "Transforming Growth Factor Beta Has Neurotrophic Actions on Sensory Neurons In Vitro and Is Synergistic With Nerve Growth Factor", Developmental Biology 152, (1992) pp. 121-132.
Nusse, et al. Cell 69, (1992), pp. 1073-1087.
Barinaga, Science 262, (1993), pp. 653-654.
Pomponi, et al., Aging 2, (1990), pp. 125-153.
Bowie, et al., Science 247, (1987), pp. 1306-1310.
Pepeu et al. 1990. Drug Design and Delivery 7: 1-10.
Jackowski. 1995. British Journal of Neurosurgery 9:303-17.
Ngo et al. 1994. The Protein Folding Problem & Tetiary Structure Prediction, Merz et al., eds., Birkhauser, Boston, pp. 491-495.
Cudny Henryk D.
Harland Richard M.
Ip Nancy Y.
Knecht Anne
Lamb Teresa
Cobert Robert J.
Fitzgerald David L.
Kemmerer Elizabeth C.
Regeneron Pharmaceuticals Inc.
Regents of University of California
LandOfFree
Human dorsal tissue affecting factor (noggin) and nucleic acids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human dorsal tissue affecting factor (noggin) and nucleic acids , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human dorsal tissue affecting factor (noggin) and nucleic acids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2395151